Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Choi, Chel Hun ^a   Song, Sang Yong ^a   Choi, Jung Joo ^a   Park, Young Ae ^a   Kang, Heeseok ^a   Kim, Tae Joong ^a   Lee, Jeong Won ^a   Kim, Byoung Gie ^a   Lee, Je Ho ^a   Bae, Duk Soo ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MITOMYCIN C; VASCULOTROPIN; VINCRISTINE; ANTINEOPLASTIC AGENT; MITOMYCIN; PARAFFIN; VASCULOTROPIN A;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SELECTION; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; SURVIVAL RATE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA; BIOSYNTHESIS; CANCER STAGING; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MITOMYCIN; NEOADJUVANT THERAPY; NEOPLASM STAGING; PARAFFIN EMBEDDING; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VINCRISTINE;

EID: 54949133334     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-295     Document Type: Article

References (23)

1. Thomas GM Improved treatment for cervical cancer - concurrent chemotherapy and radiotherapy N Engl J Med 1999, 340(15):1198-1200. 10.1056/NEJM199904153401509 10202172
2. Pignata S Silvestro G Ferrari E Selvaggi L Perrone F Maffeo A Frezza P Di Vagno G Casella G Ricchi P Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix J Clin Oncol 1999, 17(3):756-760. 10071263
3. Serur E Mathews RP Gates J Levine P Maiman M Remy JC Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix Gynecol Oncol 1997, 65(2):348-356. 10.1006/gyno.1997.4645 9159350
4. Brown LF Berse B Jackman RW Tognazzi K Guidi AJ Dvorak HF Senger DR Connolly JL Schnitt SJ Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer Hum Pathol 1995, 26(1):86-91. 10.1016/0046-8177(95)90119-1 7821921
5. Fine BA Valente PT Feinstein GI Dey T VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma Gynecol Oncol 2000, 76(1):33-39. 10.1006/gyno.1999.5658 10620438
6. Seo Y Baba H Fukuda T Takashima M Sugimachi K High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma Cancer 2000, 88(10):2239-2245. 10.1002/ (SICI)1097-0142(20000515)88:10<2239::AID-CNCR6>3.0.CO;2-V 10820344
7. Cheng WF Chen CA Lee CN Chen TM Hsieh FJ Hsieh CY Vascular endothelial growth factor in cervical carcinoma Obstet Gynecol 1999, 93(5 Pt 1):761-765. 10.1016/S0029-7844(98)00505-5 10912982
8. Cheng WF Chen CA Lee CN Wei LH Hsieh FJ Hsieh CY Vascular endothelial growth factor and prognosis of cervical carcinoma Obstet Gynecol 2000, 96(5 Pt 1):721-726. 10.1016/S0029-7844(00)01025-5 11042307
9. Loncaster JA Cooper RA Logue JP Davidson SE Hunter RD West CM Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix Br J Cancer 2000, 83(5):620-625. 10.1054/bjoc.2000.1319 10944602
10. Veikkola T Karkkainen M Claesson-Welsh L Alitalo K Regulation of angiogenesis via vascular endothelial growth factor receptors Cancer Res 2000, 60(2):203-212. 10667560
11. Choi CH Kim TJ Lee JW Kim BG Lee JH Bae DS Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma Gynecol Oncol 2007, 104(1):64-69. 10.1016/j.ygyno.2006.07.006 16904170
12. Buda A Fossati R Colombo N Fei F Floriani I Gueli Alletti D Katsaros D Landoni F Lissoni A Malzoni C Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: The SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study J Clin Oncol 2005, 23(18):4137-4145. 10.1200/JCO.2005.04.172 15961761
13. Ribeiro U Jr Finkelstein SD Safatle-Ribeiro AV Landreneau RJ Clarke MR Bakker A Swalsky PA Gooding WE Posner MC p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma Cancer 1998, 83(1):7-18. 10.1002/ (SICI)1097-0142(19980701)83:1<7::AID-CNCR2>3.0.CO;2-R 9655287
14. Kimura S Kitadai Y Tanaka S Kuwai T Hihara J Yoshida K Toge T Chayama K Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma Eur J Cancer 2004, 40(12):1904-1912. 10.1016/j.ejca.2004.04.035 15288294
15. Klement G Baruchel S Rak J Man S Clark K Hicklin DJ Bohlen P Kerbel RS Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J Clin Invest 2000, 105(8):R15-24. 517491 10772661 10.1172/JCI8829
16. Gasparini G Bonoldi E Viale G Verderio P Boracchi P Panizzoni GA Radaelli U Di Bacco A Guglielmi RB Bevilacqua P Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas Int J Cancer 1996 69 3 205 211 10.1002/ (SICI)1097-0215(19960621)69:3<205::AID-IJC10>3.0.CO;2-6 8682589
17. Raspollini MR Amunni G Villanucci A Baroni G Boddi V Taddei GL Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma Int J Gynecol Cancer 2004, 14(5):815-823. 10.1111/j.1048-891X.2004.014514.x 15361189
18. Baish JW Jain RK Fractals and cancer Cancer Res 2000, 60(14):3683-3688. 10919633
19. Jain RK The next frontier of molecular medicine: Delivery of therapeutics Nat Med 1998, 4(6):655-657. 10.1038/nm0698-655 9623964
20. Piret JP Mottet D Raes M Michiels C Is HIF-1alpha a pro- or an anti-apoptotic protein? Biochem Pharmacol 2002, 64(5-6):889-892. 10.1016/ S0006-2952(02)01155-3 12213583
21. Beasley NJ Leek R Alam M Turley H Cox GJ Gatter K Millard P Fuggle S Harris AL Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: Relationship to tumor biology and treatment outcome in surgically resected patients Cancer Res 2002, 62(9):2493-2497. 11980639
22. Tjalma W Weyler J Weyn B Van Marck E Van Daele A Van Dam P Goovaerts G Buytaert P The association between vascular endothelial growth factor, microvessel density and clinicopathological features in invasive cervical cancer Eur J Obstet Gynecol Reprod Biol 2000, 92(2):251-257. 10.1016/S0301-2115(99)00295-X 10996690
23. Jain RK The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors Microcirculation 1997, 4(1):1-23. 10.3109/10739689709148314 9110280